{"id":745057,"date":"2023-04-04T08:27:41","date_gmt":"2023-04-04T12:27:41","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/amarin-announces-vazkepa-icosapent-ethyl-approved-by-israels-ministry-of-health\/"},"modified":"2023-04-04T08:27:41","modified_gmt":"2023-04-04T12:27:41","slug":"amarin-announces-vazkepa-icosapent-ethyl-approved-by-israels-ministry-of-health","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/amarin-announces-vazkepa-icosapent-ethyl-approved-by-israels-ministry-of-health\/","title":{"rendered":"Amarin Announces VAZKEPA\u00ae (Icosapent Ethyl) Approved by Israel&#8217;s Ministry of Health"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"center\">\n        <em>&#8212; Approval of VAZKEPA\u00ae to Reduce the Risk of Cardiovascular (CV) Events in Adult Statin-Treated Patients at High CV Risk with Elevated Triglycerides and Other High-Risk Characteristics as Studied in REDUCE-IT \u2013-<\/em><br \/>\n        \n      <\/p>\n<p align=\"center\">\n        <em>&#8212; Heart Disease Second Leading Cause of Death in Men and Women Aged 45 and Older in Israel &#8212;<\/em>\n      <\/p>\n<p>DUBLIN, Ireland and BRIDGEWATER, N.J., April  04, 2023  (GLOBE NEWSWIRE) &#8212; Amarin Corporation plc (NASDAQ:AMRN) today announced that Israel\u2019s Ministry of Health (MOH) Pharmaceuticals Division has granted regulatory approval to VAZKEPA (icosapent ethyl). The MOH issued its approval of VAZKEPA to reduce the risk of cardiovascular events in adult statin-treated patients at high cardiovascular risk with elevated triglycerides (\u2265150\u00a0mg\/dL [\u2265 1.7 mmol\/L]) and either established cardiovascular disease or diabetes and at least one other cardiovascular risk factor.<\/p>\n<p align=\"justify\">\u201cAccording to data from the Israeli Ministry of Health, heart diseases are the second leading cause of death in Israel, in both men and women, aged 45 and older.<sup>i<\/sup> Heart disease accounted for about one-sixth of all male and female deaths in recent years in Israel.<sup>i<\/sup><\/p>\n<p align=\"justify\">\u201cThe regulatory approval of VAZKEPA in Israel marks continued progress in our effort to bring this product to patients with residual cardiovascular risk around the world,\u201d said Steven Ketchum, PhD., President, Research &amp; Development and Chief Scientific Officer, Amarin. \u201cWe are proud of this important milestone in that effort, and that patients in Israel may soon be able to access this important therapeutic option to address their residual cardiovascular risk.\u201d<\/p>\n<p align=\"justify\">Amarin has partnership discussions underway in this territory and will be preparing for potential pricing and reimbursement in Israel beginning in 2024.<\/p>\n<p>\n        <strong>About Amarin<\/strong>\n      <\/p>\n<p>Amarin is an innovative pharmaceutical company leading a new paradigm in cardiovascular disease management. From our foundation in scientific research to our focus on clinical trials, and now our commercial expansion, we are evolving and growing rapidly. Amarin has offices in Bridgewater, New Jersey in the United States, Dublin in Ireland, Zug in Switzerland, and other countries in Europe as well as commercial partners and suppliers around the world. We are committed to increasing the scientific understanding of the cardiovascular risk that persists beyond traditional therapies and advancing the treatment of that risk.<\/p>\n<p>\n        <strong>Forward-Looking Statements<\/strong>\n      <\/p>\n<p>This press release contains forward-looking statements which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including beliefs about Amarin\u2019s entry into Israel and continued expansion in other key international markets; Amarin\u2019s partnership discussions for Israel; the potential pricing and reimbursement for VAZKEPA in Israel beginning in 2024; and the overall potential and future success of VASCEPA (marketed as VAZKEPA in Europe) and Amarin generally. These forward-looking statements are not promises or guarantees and involve substantial risks and uncertainties. A further list and description of these risks, uncertainties and other risks associated with an investment in Amarin can be found in Amarin&#8217;s filings with the U.S. Securities and Exchange Commission, including Amarin\u2019s annual report on Form 10-K for the full year ended 2022. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date they are made. Amarin undertakes no obligation to update or revise the information contained in its forward-looking statements, whether as a result of new information, future events or circumstances or otherwise. Amarin\u2019s forward-looking statements do not reflect the potential impact of significant transactions the company may enter into, such as mergers, acquisitions, dispositions, joint ventures or any material agreements that Amarin may enter into, amend or terminate.<\/p>\n<p>\n        <strong>Availability of Other Information About Amarin<\/strong>\u00a0<\/p>\n<p>Amarin communicates with its investors and the public using the company website (www.amarincorp.com) and the investor relations website (investor.amarincorp.com), including but not limited to investor presentations and FAQs, Securities and Exchange Commission filings, press releases, public conference calls and webcasts. The information that Amarin posts on these channels and websites could be deemed to be material information. As a result, Amarin encourages investors, the media and others interested in Amarin to review the information that is posted on these channels, including the investor relations website, on a regular basis. This list of channels may be updated from time to time on Amarin\u2019s investor relations website and may include social media channels. The contents of Amarin\u2019s website or these channels, or any other website that may be accessed from its website or these channels, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933.\u00a0<\/p>\n<p>\n        <strong>Amarin Contact Information<\/strong><br \/>\n        <br \/>Investor Inquiries:<br \/>Lisa DeFrancesco<br \/>Amarin Corporation plc<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=SuQnfvP7GKiI8eReXje8ZhjInXLZykYzktoEiiy4Rbn8R-3-EldpGRHTOQHta_XMjh6nMtUKYhqkOb69KwAIKw==\" rel=\"nofollow noopener\" target=\"_blank\">IR@amarincorp.com<\/a><\/p>\n<p>Media Inquiries:<br \/>Mark Marmur<br \/>Amarin Corporation plc<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=8FfsZ09iKDzFlmkxvcdAGHAmKiVR8Y2zKT7KdKgOFtu9G9wNlpsipQ_R8v2OYQWoTN-LEFR_felAhmEM92Yc4Q==\" rel=\"nofollow noopener\" target=\"_blank\">PR@amarincorp.com<\/a><\/p>\n<hr \/>\n<p>\n        <sup>i<\/sup> Israeli Ministry of Health \u2013 Health Information Division. Leading causes of death in Israel 2000 \u2013 2019. <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=iryFUlIoulIkAyVIfbFxumXSoaI2dqqaYZONN9IlU5c2NMfxbniFnoHIJVlDkcc-0Lab7ckhIGdjVHcrBqa0sco0Ypz63u79G48IFAtjU8gu4YMGJLh03mACnn98Q9U7Of1YcPqr7sAhNSGUw1HoGY3fWafeCohJzCSS6qbeO6dDC8S75e_NMw6ziftZYqzIiqV-lf6QoYmn_O1e5h4JXsWckTjRTgxatxUfewjmhOdpO07cdwLTiS9xwSyyBN9kUpI94S7ckqcfXV0AJF9P1YSIhuSfZtwwYHfLI-qY1ZxJ7ZJVPu98VqmPeUTILQbwjDTpJ2_Vb16ngAyPJCn3oko_heqO1sZ0RbJnbeiBPecL2peLzlx1mGkSg86BaDS0eUORTpSwf2p_A53FxvbHuA==\" rel=\"nofollow noopener\" target=\"_blank\"><u>https:\/\/www.gov.il\/BlobFolder\/reports\/leading-causes-of-death-in-israel\/he\/files_publications_units_info_CausesOfDeaths2019_Summary.pdf<\/u><\/a><\/p>\n<p>\u00a0<\/p>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgwMTM3OCM1NTA4MjU3IzIwMjc3OTY=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/ZWI0NWZjMmItNzZhNC00ZTc5LWIyNDctN2ZmZDU4MGEzNmJjLTEwMzg4NDY=\/tiny\/Amarin-Corporation-plc.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>&#8212; Approval of VAZKEPA\u00ae to Reduce the Risk of Cardiovascular (CV) Events in Adult Statin-Treated Patients at High CV Risk with Elevated Triglycerides and Other High-Risk Characteristics as Studied in REDUCE-IT \u2013- &#8212; Heart Disease Second Leading Cause of Death in Men and Women Aged 45 and Older in Israel &#8212; DUBLIN, Ireland and BRIDGEWATER, N.J., April 04, 2023 (GLOBE NEWSWIRE) &#8212; Amarin Corporation plc (NASDAQ:AMRN) today announced that Israel\u2019s Ministry of Health (MOH) Pharmaceuticals Division has granted regulatory approval to VAZKEPA (icosapent ethyl). The MOH issued its approval of VAZKEPA to reduce the risk of cardiovascular events in adult statin-treated patients at high cardiovascular risk with elevated triglycerides (\u2265150\u00a0mg\/dL [\u2265 1.7 mmol\/L]) and either established cardiovascular disease or diabetes &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/amarin-announces-vazkepa-icosapent-ethyl-approved-by-israels-ministry-of-health\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Amarin Announces VAZKEPA\u00ae (Icosapent Ethyl) Approved by Israel&#8217;s Ministry of Health&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-745057","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Amarin Announces VAZKEPA\u00ae (Icosapent Ethyl) Approved by Israel&#039;s Ministry of Health - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/amarin-announces-vazkepa-icosapent-ethyl-approved-by-israels-ministry-of-health\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Amarin Announces VAZKEPA\u00ae (Icosapent Ethyl) Approved by Israel&#039;s Ministry of Health - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"&#8212; Approval of VAZKEPA\u00ae to Reduce the Risk of Cardiovascular (CV) Events in Adult Statin-Treated Patients at High CV Risk with Elevated Triglycerides and Other High-Risk Characteristics as Studied in REDUCE-IT \u2013- &#8212; Heart Disease Second Leading Cause of Death in Men and Women Aged 45 and Older in Israel &#8212; DUBLIN, Ireland and BRIDGEWATER, N.J., April 04, 2023 (GLOBE NEWSWIRE) &#8212; Amarin Corporation plc (NASDAQ:AMRN) today announced that Israel\u2019s Ministry of Health (MOH) Pharmaceuticals Division has granted regulatory approval to VAZKEPA (icosapent ethyl). The MOH issued its approval of VAZKEPA to reduce the risk of cardiovascular events in adult statin-treated patients at high cardiovascular risk with elevated triglycerides (\u2265150\u00a0mg\/dL [\u2265 1.7 mmol\/L]) and either established cardiovascular disease or diabetes &hellip; Continue reading &quot;Amarin Announces VAZKEPA\u00ae (Icosapent Ethyl) Approved by Israel&#8217;s Ministry of Health&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/amarin-announces-vazkepa-icosapent-ethyl-approved-by-israels-ministry-of-health\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-04-04T12:27:41+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgwMTM3OCM1NTA4MjU3IzIwMjc3OTY=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/amarin-announces-vazkepa-icosapent-ethyl-approved-by-israels-ministry-of-health\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/amarin-announces-vazkepa-icosapent-ethyl-approved-by-israels-ministry-of-health\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Amarin Announces VAZKEPA\u00ae (Icosapent Ethyl) Approved by Israel&#8217;s Ministry of Health\",\"datePublished\":\"2023-04-04T12:27:41+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/amarin-announces-vazkepa-icosapent-ethyl-approved-by-israels-ministry-of-health\\\/\"},\"wordCount\":806,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/amarin-announces-vazkepa-icosapent-ethyl-approved-by-israels-ministry-of-health\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgwMTM3OCM1NTA4MjU3IzIwMjc3OTY=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/amarin-announces-vazkepa-icosapent-ethyl-approved-by-israels-ministry-of-health\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/amarin-announces-vazkepa-icosapent-ethyl-approved-by-israels-ministry-of-health\\\/\",\"name\":\"Amarin Announces VAZKEPA\u00ae (Icosapent Ethyl) Approved by Israel's Ministry of Health - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/amarin-announces-vazkepa-icosapent-ethyl-approved-by-israels-ministry-of-health\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/amarin-announces-vazkepa-icosapent-ethyl-approved-by-israels-ministry-of-health\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgwMTM3OCM1NTA4MjU3IzIwMjc3OTY=\",\"datePublished\":\"2023-04-04T12:27:41+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/amarin-announces-vazkepa-icosapent-ethyl-approved-by-israels-ministry-of-health\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/amarin-announces-vazkepa-icosapent-ethyl-approved-by-israels-ministry-of-health\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/amarin-announces-vazkepa-icosapent-ethyl-approved-by-israels-ministry-of-health\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgwMTM3OCM1NTA4MjU3IzIwMjc3OTY=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgwMTM3OCM1NTA4MjU3IzIwMjc3OTY=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/amarin-announces-vazkepa-icosapent-ethyl-approved-by-israels-ministry-of-health\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Amarin Announces VAZKEPA\u00ae (Icosapent Ethyl) Approved by Israel&#8217;s Ministry of Health\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Amarin Announces VAZKEPA\u00ae (Icosapent Ethyl) Approved by Israel's Ministry of Health - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/amarin-announces-vazkepa-icosapent-ethyl-approved-by-israels-ministry-of-health\/","og_locale":"en_US","og_type":"article","og_title":"Amarin Announces VAZKEPA\u00ae (Icosapent Ethyl) Approved by Israel's Ministry of Health - Market Newsdesk","og_description":"&#8212; Approval of VAZKEPA\u00ae to Reduce the Risk of Cardiovascular (CV) Events in Adult Statin-Treated Patients at High CV Risk with Elevated Triglycerides and Other High-Risk Characteristics as Studied in REDUCE-IT \u2013- &#8212; Heart Disease Second Leading Cause of Death in Men and Women Aged 45 and Older in Israel &#8212; DUBLIN, Ireland and BRIDGEWATER, N.J., April 04, 2023 (GLOBE NEWSWIRE) &#8212; Amarin Corporation plc (NASDAQ:AMRN) today announced that Israel\u2019s Ministry of Health (MOH) Pharmaceuticals Division has granted regulatory approval to VAZKEPA (icosapent ethyl). The MOH issued its approval of VAZKEPA to reduce the risk of cardiovascular events in adult statin-treated patients at high cardiovascular risk with elevated triglycerides (\u2265150\u00a0mg\/dL [\u2265 1.7 mmol\/L]) and either established cardiovascular disease or diabetes &hellip; Continue reading \"Amarin Announces VAZKEPA\u00ae (Icosapent Ethyl) Approved by Israel&#8217;s Ministry of Health\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/amarin-announces-vazkepa-icosapent-ethyl-approved-by-israels-ministry-of-health\/","og_site_name":"Market Newsdesk","article_published_time":"2023-04-04T12:27:41+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgwMTM3OCM1NTA4MjU3IzIwMjc3OTY=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/amarin-announces-vazkepa-icosapent-ethyl-approved-by-israels-ministry-of-health\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/amarin-announces-vazkepa-icosapent-ethyl-approved-by-israels-ministry-of-health\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Amarin Announces VAZKEPA\u00ae (Icosapent Ethyl) Approved by Israel&#8217;s Ministry of Health","datePublished":"2023-04-04T12:27:41+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/amarin-announces-vazkepa-icosapent-ethyl-approved-by-israels-ministry-of-health\/"},"wordCount":806,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/amarin-announces-vazkepa-icosapent-ethyl-approved-by-israels-ministry-of-health\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgwMTM3OCM1NTA4MjU3IzIwMjc3OTY=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/amarin-announces-vazkepa-icosapent-ethyl-approved-by-israels-ministry-of-health\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/amarin-announces-vazkepa-icosapent-ethyl-approved-by-israels-ministry-of-health\/","name":"Amarin Announces VAZKEPA\u00ae (Icosapent Ethyl) Approved by Israel's Ministry of Health - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/amarin-announces-vazkepa-icosapent-ethyl-approved-by-israels-ministry-of-health\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/amarin-announces-vazkepa-icosapent-ethyl-approved-by-israels-ministry-of-health\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgwMTM3OCM1NTA4MjU3IzIwMjc3OTY=","datePublished":"2023-04-04T12:27:41+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/amarin-announces-vazkepa-icosapent-ethyl-approved-by-israels-ministry-of-health\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/amarin-announces-vazkepa-icosapent-ethyl-approved-by-israels-ministry-of-health\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/amarin-announces-vazkepa-icosapent-ethyl-approved-by-israels-ministry-of-health\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgwMTM3OCM1NTA4MjU3IzIwMjc3OTY=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgwMTM3OCM1NTA4MjU3IzIwMjc3OTY="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/amarin-announces-vazkepa-icosapent-ethyl-approved-by-israels-ministry-of-health\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Amarin Announces VAZKEPA\u00ae (Icosapent Ethyl) Approved by Israel&#8217;s Ministry of Health"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/745057","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=745057"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/745057\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=745057"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=745057"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=745057"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}